Synthesis and optimization of effective dose of niosomal amikacin for antibacterial activity on Pseudomonas aeruginosa

Document Type : Original Article

Authors

1 Department of Nanobiotechnology, Research Laboratory of Shahed University, Tehran, Iran

2 Department of Biological Engineering, Faculty of New Sciences and Technologies, University of Tehran, Tehran, Iran

Abstract

Background and Objective: Niosomes are one of the new drug delivery systems. In this synthesis study, the properties and characteristics of nanosystems loaded amikacin for the aim of slow releasing and antibacterial activity on Pseudomonas aeruginosa were been investigated.
Materials and Methods: The synthesis nanocarriers were characterized by using DLS, zeta potential, SEM images, and FTIR analysis. The percentage of drug loading in the nanosystems were measured. After that, the release rate of the drug was checked. MIC microbiological tests were performed to determine the minimum inhibitory concentration (MIC) of Pseudomonas aeruginosa. Finally, with MTT method, the toxicity and effectiveness of the system on cell line A549 extracted from lung were evaluated.
Results: In this study, by synthesis and optimization, with the highest loading efficiency of 95.15% at the formulations and the slowest release with a drug release rate of 65.27% in 60 hours to reduce the side effects of amikacin. We were able to increase the antimicrobial activity of amikacin niosomal against Pseudomonas aeruginosa and reduce the side effects compared to the free form and have a slower and more continuous release with greater effectiveness on bacteria. Studying this process on the lung cell lines was successful and free-form of amikacin has a more toxic effect than two drug-free and drug-free niosomal systems. Numerous mathematical models, including realistic and experimental/quasi-experimental mechanistic models, have been successfully introduced to quantitatively define drug release mechanisms and play an important role in designing a drug delivery system for drug release diagrams. That reported in results
Conclusion: Achieving optimal conditions for the preparation of nanosystems carrying amikacin and investigating the effect of this system on bacterial agents is an important step in science, research, and economic efficiency.

Keywords

References

  1. Akram M, Shahid M, Khan AU. Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in J N M C Hospital Aligarh, India. Annals of Clinical Microbiology and Antimicrobials 2007;6:4.
  2. Delissalde F, Amábile-Cuevas CF. Comparison of antibiotic susceptibility and plasmid content, between biofilm producing and non-producing clinical isolates of Pseudomonas aeruginosa. International Journal of Antimicrobial Agents 2004;24(4):405-8.
  3. Sharp PM, Saenz CA, Martin RR. Amikacin (BB-K8) treatment of multiple-drug-resistant Proteus infections. Antimicrobial Agents and Chemotherapy 1974;5(5):435-8.
  4. Brzozowski M, Krukowska Ż, Galant K, Jursa-Kulesza J, Kosik-Bogacka D. Genotypic characterisation and antimicrobial resistance of Pseudomonas aeruginosa strains isolated from patients of different hospitals and medical centres in Poland. BMC Infectious Diseases 2020;20(1):693.
  5. Taber SS, Pasko DA. The epidemiology of drug-induced disorders: the kidney. Expert Opinion on Drug Safety 2008;7(6):679-90.
  6. Beauchamp D, Labrecque G. Aminoglycoside nephrotoxicity: do time and frequency of administration matter? Current Opinion in Critical Care 2001;7(6):401-8.
  7. Rougier F, Claude D, Maurin M, Sedoglavic A, Ducher M, Corvaisier S, et al. Aminoglycoside nephrotoxicity: modeling, simulation, and control. Antimicrobial Agents and Chemotherapy 2003;47(3):1010-6.
  8. Meers P, Neville M, Malinin V, Scotto A, Sardaryan G, Kurumunda R, et al. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. Journal of Antimicrobial Chemotherapy 2008;61(4):859-68.
  9. Zhang L, Gu F, Chan J, Wang A, Langer R, Farokhzad O. Nanoparticles in medicine: therapeutic applications and developments. Clinical Pharmacology and Therapeutics 2008;83(5):761-9.
  10. Abdelbary G, El-gendy N. Niosome-encapsulated gentamicin for ophthalmic controlled delivery. AAPS PharmSciTech 2008;9(3):740-7.
  11. Valeria Shakhova VB, Elena Kastarnovaو Vladimir Orobets, Elena Grudeva. Niosomes: a promising drug delivery system. E3S Web of Conferences 2020;175:07003.
  12. Makeshwar KB, Wasankar SR. Niosome: a Novel Drug Delivery System. Asian Journal of Pharmaceutical Research 2013;3(1):16-20.
  13. G DB, P VL. Recent advances of non-ionic surfactant-based nano-vesicles (niosomes and proniosomes): a brief review of these in enhancing transdermal delivery of drug. Future Journal of Pharmaceutical Sciences 2020;6(1):100.
  14. Khan A, Sharma PK, Visht S, Malviya R. Niosomes as colloidal drug delivery system: a review. Journal of Chronotherapy and Drug Delivery 2011;2(1):15-21.
  15. Chandu VP, Arunachalam A, Jeganath S, Yamini K, Tharangini K, Chaitanya G. Niosomes: a novel drug delivery system. International Journal of Novel Trends in Pharmaceutical Sciences 2012;2(1):25-31.
  16. Sultan A, Jers C, Ganief TA, Shi L, Senissar M, Køhler JB, et al. Phosphoproteome Study of Escherichia coli Devoid of Ser/Thr Kinase YeaG During the Metabolic Shift From Glucose to Malate. Frontiers in Microbiology 2021;12.
  17. Mohamad EA, Fahmy HM. Niosomes and liposomes as promising carriers for dermal delivery of Annona squamosa extract. Brazilian Journal of Pharmaceutical Sciences 2020;56:e18096.
  18. Agarwal R, Katare O, Vyas S. Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. International Journal of Pharmaceutics 2001;228(1):43-52.

  19. 100
     
    Xu X, Costa AP, Khan MA, Burgess DJ. Application of quality by design to formulation and processing of protein liposomes. International Journal of Pharmaceutics 2012;434(1):349-59.
  20. Vidakovic B. Statistics for bioengineering sciences: with MATLAB and WinBUGS Support. Springer Science & Business Media 2011;2nd edn:623.
  21. Gianasi E, Cociancich F, Uchegbu IF, Florence AT, Duncan R. Pharmaceutical and biological characterisation of a doxorubicin-polymer conjugate (PK1) entrapped in sorbitan monostearate Span 60 niosomes. International Journal of Pharmaceutics 1997;148(2):139-48.
  22. Cable C. An examination of the effect of surface modifications on the physicochemical and biological properties of non-ionic surfactant vesicles: University of Strathclyde 1990.
  23. Devaraj GN, Parakh S, Devraj R, Apte S, Rao BR, Rambhau D. Release studies on niosomes containing fatty alcohols as bilayer stabilizers instead of cholesterol. Journal of Colloid and Interface Science 2002;251(2):360-5.
  24. Betageri G, Parsons D. Drug encapsulation and release from multilamellar and unilamellar liposomes. International Journal of Pharmaceutics 1992;81(2-3):235-41.
  25. Rogerson A, Cummings J, Florence AT. Adriamycin-loaded niosomes: drug entrapment, stability and release. Journal of Microencapsulation 1987;4(4):321-8.
Daneshvar Medicine
Volume 29, Issue 6 - Serial Number 157
March and April 2022
Pages 86-100

Files

Share

How to cite

Statistics